Robert Zurier
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cannabinoids | 7 | 2009 | 26 | 2.100 |
Why?
| Anti-Inflammatory Agents | 8 | 2009 | 81 | 1.630 |
Why?
| gamma-Linolenic Acid | 14 | 2002 | 16 | 1.570 |
Why?
| Arthritis, Rheumatoid | 19 | 2008 | 232 | 1.540 |
Why?
| Interleukin-1 | 9 | 2003 | 148 | 1.380 |
Why?
| Monocytes | 10 | 2008 | 299 | 1.340 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 8 | 2009 | 152 | 1.330 |
Why?
| Inflammation | 10 | 2009 | 666 | 1.150 |
Why?
| Synovial Membrane | 5 | 2008 | 28 | 1.120 |
Why?
| Leukocytes, Mononuclear | 5 | 2008 | 214 | 0.860 |
Why?
| Eicosanoids | 8 | 2009 | 18 | 0.840 |
Why?
| Synovial Fluid | 8 | 2008 | 26 | 0.830 |
Why?
| Fatty Acids | 9 | 2007 | 134 | 0.780 |
Why?
| T-Lymphocytes | 7 | 2003 | 898 | 0.760 |
Why?
| Arachidonic Acids | 5 | 2009 | 23 | 0.740 |
Why?
| Prostaglandins | 6 | 2008 | 32 | 0.650 |
Why?
| Analgesics | 3 | 2007 | 67 | 0.630 |
Why?
| Plant Oils | 6 | 2009 | 48 | 0.600 |
Why?
| Cells, Cultured | 17 | 2008 | 1799 | 0.580 |
Why?
| Antirheumatic Agents | 3 | 2007 | 113 | 0.570 |
Why?
| Endocannabinoids | 3 | 2009 | 10 | 0.560 |
Why?
| Lymphocyte Activation | 7 | 2008 | 686 | 0.550 |
Why?
| PPAR gamma | 3 | 2007 | 58 | 0.540 |
Why?
| Fatty Acids, Unsaturated | 4 | 1999 | 29 | 0.540 |
Why?
| Pain | 2 | 2004 | 222 | 0.530 |
Why?
| Cannabis | 4 | 2009 | 12 | 0.520 |
Why?
| Macrophages | 5 | 2008 | 729 | 0.470 |
Why?
| Glycine | 3 | 2009 | 39 | 0.470 |
Why?
| Apoptosis | 2 | 2008 | 868 | 0.470 |
Why?
| Fibroblasts | 3 | 2009 | 287 | 0.470 |
Why?
| Rheumatic Diseases | 2 | 2002 | 21 | 0.460 |
Why?
| Humans | 45 | 2014 | 34160 | 0.460 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2007 | 489 | 0.450 |
Why?
| Interleukin-6 | 2 | 2007 | 231 | 0.440 |
Why?
| Lipoxins | 1 | 2009 | 6 | 0.430 |
Why?
| Arachidonic Acid | 6 | 2008 | 45 | 0.420 |
Why?
| Arthritis, Experimental | 5 | 2007 | 36 | 0.410 |
Why?
| Psychotropic Drugs | 2 | 2008 | 59 | 0.400 |
Why?
| Arthritis | 3 | 2005 | 41 | 0.390 |
Why?
| Osteoclasts | 1 | 2008 | 62 | 0.390 |
Why?
| Linolenic Acids | 4 | 1991 | 5 | 0.370 |
Why?
| Animals | 19 | 2014 | 14706 | 0.340 |
Why?
| Eicosapentaenoic Acid | 3 | 1997 | 11 | 0.340 |
Why?
| 8,11,14-Eicosatrienoic Acid | 6 | 1999 | 19 | 0.340 |
Why?
| Dose-Response Relationship, Drug | 7 | 2014 | 694 | 0.330 |
Why?
| Cell Differentiation | 2 | 2008 | 1046 | 0.320 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2004 | 7 | 0.320 |
Why?
| Cannabidiol | 1 | 2004 | 3 | 0.320 |
Why?
| Knee Joint | 1 | 2005 | 66 | 0.310 |
Why?
| Dietary Fats, Unsaturated | 2 | 1997 | 23 | 0.300 |
Why?
| Mice | 9 | 2014 | 7381 | 0.300 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2003 | 31 | 0.300 |
Why?
| Cyclooxygenase 2 | 4 | 2008 | 54 | 0.290 |
Why?
| Rats | 9 | 2009 | 1762 | 0.280 |
Why?
| RNA, Messenger | 5 | 2008 | 1255 | 0.280 |
Why?
| Eicosanoic Acids | 2 | 1994 | 3 | 0.270 |
Why?
| Sialoglycoproteins | 1 | 2002 | 20 | 0.270 |
Why?
| Liver Diseases | 1 | 2002 | 95 | 0.260 |
Why?
| Adjuvants, Immunologic | 4 | 2000 | 194 | 0.240 |
Why?
| Prostaglandins E | 4 | 1991 | 23 | 0.220 |
Why?
| Interleukin-8 | 3 | 2005 | 88 | 0.220 |
Why?
| Dinoprostone | 3 | 1994 | 46 | 0.210 |
Why?
| Disease Models, Animal | 4 | 2009 | 1190 | 0.200 |
Why?
| Cell Division | 3 | 2003 | 431 | 0.200 |
Why?
| Drug Evaluation, Preclinical | 2 | 2009 | 62 | 0.200 |
Why?
| Receptors, Antigen, T-Cell | 1 | 1999 | 227 | 0.190 |
Why?
| Fish Oils | 2 | 1995 | 30 | 0.190 |
Why?
| Administration, Oral | 4 | 2002 | 202 | 0.190 |
Why?
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 27 | 0.190 |
Why?
| Male | 14 | 2009 | 17242 | 0.180 |
Why?
| Interleukin-2 | 3 | 1994 | 166 | 0.180 |
Why?
| Phospholipases | 2 | 1986 | 7 | 0.170 |
Why?
| Phospholipases A | 2 | 1986 | 11 | 0.170 |
Why?
| Type C Phospholipases | 2 | 1986 | 38 | 0.170 |
Why?
| Arthritis, Psoriatic | 2 | 2008 | 12 | 0.170 |
Why?
| Cell Proliferation | 3 | 2008 | 667 | 0.170 |
Why?
| Neutrophils | 2 | 2009 | 265 | 0.170 |
Why?
| Protein Kinase C | 1 | 1995 | 104 | 0.160 |
Why?
| Immune System | 1 | 1995 | 98 | 0.160 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2014 | 5 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2014 | 5 | 0.150 |
Why?
| Liposomes | 1 | 1994 | 71 | 0.150 |
Why?
| Gene Expression | 3 | 2005 | 611 | 0.150 |
Why?
| Immunity, Cellular | 2 | 1993 | 175 | 0.150 |
Why?
| Pregnancy Complications | 1 | 1997 | 221 | 0.150 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 127 | 0.140 |
Why?
| Female | 12 | 2014 | 18881 | 0.140 |
Why?
| T-Lymphocyte Subsets | 1 | 1994 | 229 | 0.140 |
Why?
| Molecular Structure | 2 | 2003 | 214 | 0.140 |
Why?
| Cell Survival | 3 | 1999 | 450 | 0.130 |
Why?
| Receptors, Cannabinoid | 2 | 2009 | 6 | 0.130 |
Why?
| Membrane Proteins | 3 | 2005 | 650 | 0.130 |
Why?
| Polyunsaturated Alkamides | 2 | 2002 | 6 | 0.130 |
Why?
| Middle Aged | 8 | 2008 | 9874 | 0.130 |
Why?
| Structure-Activity Relationship | 2 | 2014 | 263 | 0.120 |
Why?
| Chemotactic Factors | 1 | 1991 | 21 | 0.120 |
Why?
| Antibody Formation | 1 | 1991 | 103 | 0.120 |
Why?
| Synovitis | 4 | 1999 | 16 | 0.120 |
Why?
| Adult | 8 | 2008 | 9698 | 0.110 |
Why?
| Acute-Phase Reaction | 1 | 1989 | 9 | 0.110 |
Why?
| Fibromyalgia | 1 | 2009 | 7 | 0.110 |
Why?
| Peritonitis | 1 | 2009 | 22 | 0.110 |
Why?
| Isoenzymes | 2 | 2000 | 131 | 0.100 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 24 | 0.100 |
Why?
| RANK Ligand | 1 | 2008 | 30 | 0.100 |
Why?
| Anilides | 1 | 2007 | 8 | 0.100 |
Why?
| Liver | 2 | 2002 | 542 | 0.100 |
Why?
| Cell Separation | 3 | 2008 | 133 | 0.100 |
Why?
| Drug Design | 2 | 2007 | 89 | 0.100 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2008 | 123 | 0.100 |
Why?
| Prostaglandin Antagonists | 1 | 2007 | 4 | 0.090 |
Why?
| Phorbol Esters | 1 | 2007 | 6 | 0.090 |
Why?
| Cell Culture Techniques | 1 | 2008 | 120 | 0.090 |
Why?
| Chromatography, Thin Layer | 1 | 2007 | 16 | 0.090 |
Why?
| Alanine | 1 | 2007 | 38 | 0.090 |
Why?
| Spectrophotometry, Ultraviolet | 1 | 2007 | 42 | 0.090 |
Why?
| Indicators and Reagents | 1 | 2007 | 46 | 0.090 |
Why?
| Edema | 1 | 2007 | 31 | 0.090 |
Why?
| Matrix Metalloproteinases | 1 | 2007 | 16 | 0.090 |
Why?
| Interleukin-1alpha | 1 | 2007 | 18 | 0.090 |
Why?
| Lipopolysaccharides | 2 | 2001 | 516 | 0.090 |
Why?
| Cartilage | 1 | 2007 | 26 | 0.090 |
Why?
| Sulfhydryl Compounds | 1 | 2007 | 39 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2009 | 344 | 0.090 |
Why?
| Signal Transduction | 4 | 1999 | 2304 | 0.090 |
Why?
| Chronic Disease | 4 | 2007 | 536 | 0.090 |
Why?
| Aspirin | 1 | 1987 | 160 | 0.090 |
Why?
| Embryo, Mammalian | 1 | 2007 | 121 | 0.090 |
Why?
| Transcription Factors | 2 | 2004 | 1200 | 0.090 |
Why?
| Stem Cells | 1 | 2008 | 202 | 0.090 |
Why?
| Leukocytes | 1 | 2007 | 107 | 0.090 |
Why?
| Mice, Inbred BALB C | 1 | 2008 | 806 | 0.090 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2007 | 225 | 0.090 |
Why?
| Blood Platelets | 3 | 1996 | 238 | 0.080 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2004 | 11 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2005 | 110 | 0.080 |
Why?
| Cytokines | 3 | 2008 | 719 | 0.080 |
Why?
| Dexamethasone | 1 | 2005 | 85 | 0.080 |
Why?
| Cell Membrane | 1 | 2007 | 418 | 0.080 |
Why?
| Osteoarthritis, Knee | 1 | 2005 | 49 | 0.080 |
Why?
| Joints | 1 | 2003 | 26 | 0.070 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2003 | 17 | 0.070 |
Why?
| Annexin A5 | 1 | 2003 | 26 | 0.070 |
Why?
| DNA Fragmentation | 1 | 2003 | 32 | 0.070 |
Why?
| Aged | 5 | 2008 | 7641 | 0.070 |
Why?
| Antigens, CD3 | 2 | 2008 | 60 | 0.070 |
Why?
| Cyclic AMP | 2 | 1989 | 124 | 0.070 |
Why?
| Clinical Trials as Topic | 2 | 1995 | 309 | 0.070 |
Why?
| Caspase 3 | 1 | 2003 | 76 | 0.070 |
Why?
| Still's Disease, Adult-Onset | 1 | 2002 | 2 | 0.070 |
Why?
| Behavior | 1 | 2003 | 37 | 0.070 |
Why?
| Hemochromatosis | 1 | 2002 | 8 | 0.070 |
Why?
| Flow Cytometry | 1 | 2005 | 615 | 0.070 |
Why?
| Scleroderma, Systemic | 1 | 2002 | 8 | 0.070 |
Why?
| Double-Blind Method | 2 | 1994 | 489 | 0.070 |
Why?
| Spondylitis, Ankylosing | 1 | 2002 | 16 | 0.070 |
Why?
| Lymphocytes | 2 | 1995 | 181 | 0.070 |
Why?
| Cell Line | 1 | 2007 | 1755 | 0.070 |
Why?
| Caspases | 1 | 2003 | 135 | 0.070 |
Why?
| RNA Stability | 1 | 2003 | 70 | 0.070 |
Why?
| Mice, Knockout | 1 | 2007 | 1607 | 0.070 |
Why?
| Sjogren's Syndrome | 1 | 2002 | 12 | 0.070 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 15 | 0.070 |
Why?
| Phenotype | 1 | 2005 | 803 | 0.070 |
Why?
| Lipids | 2 | 1996 | 230 | 0.070 |
Why?
| Microscopy, Fluorescence | 1 | 2003 | 362 | 0.060 |
Why?
| Biopsy | 1 | 2002 | 263 | 0.060 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2001 | 57 | 0.060 |
Why?
| Phagocytes | 2 | 1995 | 45 | 0.060 |
Why?
| Fatty Acids, Essential | 2 | 1993 | 8 | 0.060 |
Why?
| Protein Precursors | 1 | 2001 | 67 | 0.060 |
Why?
| Macrophage Activation | 1 | 2001 | 100 | 0.060 |
Why?
| Membrane Lipids | 2 | 1993 | 26 | 0.060 |
Why?
| Hydrolysis | 1 | 2000 | 104 | 0.060 |
Why?
| Oxidation-Reduction | 1 | 2000 | 228 | 0.050 |
Why?
| Uric Acid | 2 | 1989 | 39 | 0.050 |
Why?
| Linoleic Acids | 2 | 1988 | 9 | 0.050 |
Why?
| Inflammation Mediators | 1 | 1999 | 134 | 0.050 |
Why?
| Injections, Intradermal | 1 | 1998 | 4 | 0.050 |
Why?
| Freund's Adjuvant | 1 | 1998 | 10 | 0.050 |
Why?
| Palmitic Acid | 1 | 1997 | 8 | 0.050 |
Why?
| Leukemia, Monocytic, Acute | 1 | 1997 | 5 | 0.050 |
Why?
| Injections, Subcutaneous | 1 | 1998 | 54 | 0.050 |
Why?
| Rats, Inbred Lew | 1 | 1998 | 87 | 0.050 |
Why?
| Cyclooxygenase 1 | 1 | 1998 | 11 | 0.050 |
Why?
| Safflower Oil | 1 | 1997 | 2 | 0.050 |
Why?
| Flax | 1 | 1997 | 4 | 0.050 |
Why?
| Immunosuppressive Agents | 1 | 1999 | 204 | 0.050 |
Why?
| Helianthus | 1 | 1997 | 4 | 0.050 |
Why?
| 3T3 Cells | 1 | 1998 | 98 | 0.050 |
Why?
| Binding Sites | 2 | 2014 | 749 | 0.050 |
Why?
| Antigens, CD | 2 | 2007 | 292 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 1997 | 383 | 0.050 |
Why?
| Placebos | 1 | 1996 | 66 | 0.050 |
Why?
| Phospholipases A2 | 2 | 1986 | 14 | 0.040 |
Why?
| Skin | 1 | 1998 | 229 | 0.040 |
Why?
| Fatty Acids, Omega-6 | 1 | 1995 | 5 | 0.040 |
Why?
| Acute Disease | 2 | 1994 | 529 | 0.040 |
Why?
| Kinetics | 1 | 1997 | 709 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2007 | 2864 | 0.040 |
Why?
| Translocation, Genetic | 1 | 1995 | 53 | 0.040 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 1995 | 13 | 0.040 |
Why?
| Docosahexaenoic Acids | 1 | 1995 | 14 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2001 | 1217 | 0.040 |
Why?
| HL-60 Cells | 1 | 2014 | 18 | 0.040 |
Why?
| Molecular Conformation | 1 | 2014 | 97 | 0.040 |
Why?
| Time Factors | 2 | 1997 | 2605 | 0.040 |
Why?
| Endothelium, Vascular | 1 | 1995 | 186 | 0.040 |
Why?
| Pain Measurement | 1 | 2014 | 191 | 0.040 |
Why?
| Alprostadil | 1 | 1993 | 9 | 0.040 |
Why?
| Behavior, Animal | 1 | 2014 | 136 | 0.040 |
Why?
| Rats, Sprague-Dawley | 1 | 1994 | 475 | 0.040 |
Why?
| Chi-Square Distribution | 1 | 1993 | 366 | 0.030 |
Why?
| Pregnancy | 1 | 1997 | 1207 | 0.030 |
Why?
| Phagocytosis | 2 | 1988 | 193 | 0.030 |
Why?
| Dietary Fats | 1 | 1993 | 205 | 0.030 |
Why?
| SRS-A | 1 | 1990 | 2 | 0.030 |
Why?
| Chemokine CCL2 | 1 | 1991 | 54 | 0.030 |
Why?
| Leukotriene B4 | 1 | 1990 | 14 | 0.030 |
Why?
| Severity of Illness Index | 1 | 1994 | 893 | 0.030 |
Why?
| Blotting, Northern | 1 | 1991 | 158 | 0.030 |
Why?
| Blood Cells | 1 | 1990 | 24 | 0.030 |
Why?
| Prospective Studies | 1 | 1994 | 1668 | 0.030 |
Why?
| Receptors, Interleukin-2 | 1 | 1990 | 68 | 0.030 |
Why?
| Indomethacin | 1 | 1989 | 24 | 0.030 |
Why?
| Recombinant Proteins | 1 | 1991 | 612 | 0.030 |
Why?
| Rats, Inbred Strains | 1 | 1988 | 170 | 0.030 |
Why?
| Tumor Necrosis Factors | 1 | 2008 | 11 | 0.030 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 39 | 0.030 |
Why?
| Antigens, CD28 | 1 | 2008 | 41 | 0.030 |
Why?
| Immunophenotyping | 1 | 2008 | 167 | 0.020 |
Why?
| Forkhead Transcription Factors | 1 | 2008 | 83 | 0.020 |
Why?
| Adolescent | 1 | 1996 | 4025 | 0.020 |
Why?
| Linoleic Acid | 1 | 1987 | 16 | 0.020 |
Why?
| Treatment Outcome | 1 | 1994 | 2667 | 0.020 |
Why?
| Phospholipids | 1 | 1987 | 66 | 0.020 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2007 | 108 | 0.020 |
Why?
| Telomere | 1 | 2007 | 32 | 0.020 |
Why?
| Models, Chemical | 1 | 2007 | 125 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2007 | 286 | 0.020 |
Why?
| Ligands | 1 | 2007 | 337 | 0.020 |
Why?
| Phosphatidylcholines | 1 | 1985 | 31 | 0.020 |
Why?
| Diet | 1 | 1989 | 460 | 0.020 |
Why?
| Age Factors | 1 | 2008 | 1100 | 0.020 |
Why?
| Case-Control Studies | 1 | 2007 | 660 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2007 | 685 | 0.020 |
Why?
| Protein Conformation | 1 | 2007 | 600 | 0.020 |
Why?
| Arthus Reaction | 1 | 1983 | 1 | 0.020 |
Why?
| Mice, Inbred NZB | 1 | 1983 | 12 | 0.020 |
Why?
| Dermatitis, Contact | 1 | 1983 | 8 | 0.020 |
Why?
| Chemistry | 1 | 1983 | 19 | 0.020 |
Why?
| Sheep | 1 | 1983 | 88 | 0.020 |
Why?
| Chemical Phenomena | 1 | 1983 | 79 | 0.020 |
Why?
| Crystallization | 1 | 1983 | 77 | 0.020 |
Why?
| Granuloma | 1 | 1983 | 30 | 0.020 |
Why?
| Exudates and Transudates | 2 | 1973 | 10 | 0.020 |
Why?
| Bone Resorption | 1 | 1983 | 44 | 0.020 |
Why?
| Models, Molecular | 1 | 2007 | 880 | 0.020 |
Why?
| Protein Binding | 1 | 2007 | 1223 | 0.020 |
Why?
| Cattle | 1 | 1983 | 275 | 0.020 |
Why?
| Rabbits | 1 | 1983 | 322 | 0.020 |
Why?
| Dogs | 1 | 1983 | 239 | 0.020 |
Why?
| Adipocytes | 1 | 2003 | 167 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2003 | 579 | 0.010 |
Why?
| Thapsigargin | 1 | 1997 | 19 | 0.010 |
Why?
| Inositol Phosphates | 1 | 1997 | 19 | 0.010 |
Why?
| Enzyme Inhibitors | 1 | 1997 | 279 | 0.010 |
Why?
| Umbilical Veins | 1 | 1995 | 20 | 0.010 |
Why?
| Consensus Sequence | 1 | 1995 | 32 | 0.010 |
Why?
| Muscle, Smooth, Vascular | 1 | 1995 | 47 | 0.010 |
Why?
| Sequence Alignment | 1 | 1995 | 265 | 0.010 |
Why?
| Calcium | 1 | 1997 | 503 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 1997 | 685 | 0.010 |
Why?
| Glucuronidase | 1 | 1973 | 11 | 0.010 |
Why?
| Stimulation, Chemical | 1 | 1973 | 18 | 0.010 |
Why?
| L-Lactate Dehydrogenase | 1 | 1973 | 17 | 0.010 |
Why?
| Adrenalectomy | 1 | 1973 | 23 | 0.010 |
Why?
| Adrenal Glands | 1 | 1973 | 30 | 0.010 |
Why?
| Pituitary Gland | 1 | 1973 | 58 | 0.010 |
Why?
| Tarsal Joints | 1 | 1973 | 4 | 0.010 |
Why?
| Glycosaminoglycans | 1 | 1973 | 14 | 0.010 |
Why?
| Cartilage, Articular | 1 | 1973 | 22 | 0.010 |
Why?
| Tibia | 1 | 1973 | 30 | 0.010 |
Why?
| Staining and Labeling | 1 | 1973 | 103 | 0.010 |
Why?
| Base Sequence | 1 | 1995 | 1245 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1995 | 1491 | 0.010 |
Why?
| Mycobacterium tuberculosis | 1 | 1973 | 187 | 0.010 |
Why?
| Transcription, Genetic | 1 | 1995 | 786 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1995 | 2049 | 0.010 |
Why?
|
|
Zurier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|